Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THR-149 in Diabetic Macular Edema
NCT03511898Phase 1Completed
- Sponsor
- Oxurion
- Start
- May 2018
- Primary completion
- May 2019
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of THR-149 in diabetic macular edema (DME) (3 arms), sponsored by Oxurion. Primary endpoint: Incidence of dose-limiting toxicities at Day 14. Started May 2018; status: completed.
02
Drugs
THR-149
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03511898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511898.